- 3.1.1 2023 Update to guidelines
- 3.1.2 Summary of trial evidence on kidney disease progression
- 3.1.3 Summary of trial evidence on cardiovascular risk
- 3.1.4 Benefits and risks of SGLT-2 inhibition in people without type 2 DM
- 3.1.5 Quality of the evidence
- 3.1.6 Summary of published cost-effective analyses
Navigate to sections